??????????????????????????????????????????????????
Sacco?et?al.TheJournalofHeadacheandPainPage10of10
Received:3August2022Accepted:21September202222.HarrisPA,TaylorR,ThielkeR,PayneJ,GonzalezN,CondeJG(2009)
Researchelectronicdatacapture(REDCap)ametadatadrivenmethod
ologyandworkflowprocessforprovidingtranslationalresearchinformat
icssupport.JBiomedInform42(2):377–381
23.MunjalS,SinghP,ReedML,FanningK,SchwedtTJ,DodickDWetal(2020)
Mostbothersomesymptominpersonswithmigraine:resultsfromthe
References
migraineinAmericasymptomsandtreatment(MAST)study.Headache.
1.MaassenVanDenBrinkA,SaxenaPR(2004)Coronaryvasoconstrictor
60(2):416–429
potentialoftriptans:areviewofinvitropharmacologicdata.Headache.
24.AlmasM,TepperSJ,LandyS,SchweizerE,RamosE(2014)Consistency
44(Suppl1):S13–S19
ofeletriptanintreatingmigraine:resultsofarandomized,withinpatient
2.LabastidaRamirezA,RubioBeltranE,HaanesKA,ChanKY,Garrelds
multipledosestudy.Cephalalgia.34(2):126–135
IM,JohnsonKWetal(2020)Lasmiditaninhibitscalcitoningene
25.AshfordE,SalonenR,SaiersJ,WoessnerM(1998)Consistencyofresponse
relatedpeptidereleaseintherodenttrigeminovascularsystem.Pain.
tosumatriptannasalsprayacrosspatientsubgroupsandmigrainetypes.
161(5):1092–1099
Cephalalgia.18(5):273–277
3.RamirezRosasMB,LabruijereS,VillalonCM,MaassenVandenbrink
26.DahlofCG,DodickD,DowsonAJ,PascualJ(2002)Howdoesalmotriptan
A(2013)Activationof5hydroxytryptamine1B/1D/1Freceptorsasa
comparewithothertriptans?Areviewofdatafromplacebocontrolled
mechanismofactionofantimigrainedrugs.ExpertOpinPharmacother
clinicaltrials.Headache.42(2):99–113
14(12):1599–1610
27.DahlofCG,LiptonRB,McCarrollKA,KramerMS,LinesCR,FerrariMD
4.TfeltHansenP,DeVriesP,SaxenaPR(2000)Triptansinmigraine:acom
(2000)Withinpatientconsistencyofresponseofrizatriptanfortreating
parativereviewofpharmacology,pharmacokineticsandefficacy.Drugs.
migraine.Neurology.55(10):1511–1516
60(6):1259–1287
28.DowsonAJ,CharlesworthBR,PurdyA,BeckerWJ,BoesHansenS,Farkkila
5.AhnAH,BasbaumAI(2005)Wheredotriptansactinthetreatmentof
M(2003)Tolerabilityandconsistencyofeffectofzolmitriptannasalspray
migraine?Pain.115(1–2):1–4
inalongtermmigrainetreatmenttrial.CNSDrugs17(11):839–851
6.FerrariMD,GoadsbyPJ,RoonKI,LiptonRB(2002)Triptans(serotonin,
29.McGinleyJS,BuseDC,ShulmanKJ,WirthRJ,HugentoblerE,Lipton
5HT1B/1Dagonists)inmigraine:detailedresultsandmethodsofameta
RB(2019)Evaluatingmeanlevelandwithinpersonconsistencyin
analysisof53trials.Cephalalgia.22(8):633–658
migrainepainintensityandmigrainerelateddisabilityforAVP825vs
7.SteinerTJ,JensenR,KatsaravaZ,LindeM,MacGregorEA,OsipovaVetal
OralSumatriptan:resultsfromtheCOMPASSstudy,ARandomizedTrial.
(2019)Aidstomanagementofheadachedisordersinprimarycare(2nd
Headache59(7):1002–1013
edition):onbehalfoftheeuropeanheadachefederationandlifting
30.PascualJ,FalkRM,PiessensF,PrusinskiA,DocekalP,RobertMetal(2000)
theburden:theglobalcampaignagainstheadache.JHeadachePain.
Consistentefficacyandtolerabilityofalmotriptanintheacutetreatment
20(1):57
ofmultiplemigraineattacks:resultsofalarge,randomized,doubleblind,
8.DienerHC,LimmrothV(2001)Advancesinpharmacologicaltreatmentof
placebocontrolledstudy.Cephalalgia.20(6):588–596
migraine.ExpertOpinInvestigDrugs10(10):1831–1845
31.SilbersteinS,WinnerPK,McAllisterPJ,TepperSJ,HalkerR,MahmoudRA
9.VianaM,GenazzaniAA,TerrazzinoS,NappiG,GoadsbyPJ(2013)
etal(2017)Earlyonsetofefficacyandconsistencyofresponseacross
Triptannonresponders:dotheyexistandwhoarethey?Cephalalgia.
multiplemigraineattacksfromtherandomizedCOMPASSstudy:AVP
33(11):891–896
825breathpowered((R))exhalationdeliverysystem(Sumatriptannasal
10.FerrariA,PinettiD,BertoliniA,CocciaC,SternieriE(2008)Interindividual
powder)vsOralSumatriptan.Headache.57(6):862–876
variabilityoforalsumatriptanpharmacokineticsandofclinicalresponse
32.TuchmanM,EdvinssonL,GeraudG,KorczynA,MauskopA,PfaffenrathV
inmigrainepatients.EurJClinPharmacol64(5):489–495
(1999)Zolmitriptanprovidesconsistentmigrainereliefwhenusedinthe
11.MaassenVanDenBrinkA,VergouweMN,OphoffRA,SaxenaPR,FerrariMD,
longterm.CurrMedResOpin15(4):272–281
FrantsRR(1998)5HT1Breceptorpolymorphismandclinicalresponseto
33.CapiM,DeAngelisV,DeBernardiniD,DeLucaO,CipollaF,LionettoL
sumatriptan.Headache.38(4):288–291
etal(2021)CGRPreceptorantagonistsand5HT1Freceptoragonistin
12.MehrotraS,VanmolkotKR,FrantsRR,vandenMaagdenbergAM,Ferrari
thetreatmentofmigraine.JClinMed10(7):1429.
MD,MaassenVanDenBrinkA(2007)Thephe124CysandA161Tvariants
34.deVriesT,VillalonCM,MaassenVanDenBrinkA(2020)Pharmacological
ofthehuman5HT1Breceptorgenearenotmajordeterminantsofthe
treatmentofmigraine:CGRPand5HTbeyondthetriptans.Pharmacol
clinicalresponsetosumatriptan.Headache.47(5):711–716
Ther211:107528
13.DahlofCG(2006)Infrequentornonresponsetooralsumatriptandoes
35.CroopR,GoadsbyPJ,StockDA,ConwayCM,ForshawM,StockEGetal
notpredictresponsetoothertriptansreviewoffourtrials.Cephalalgia.
(2019)Efficacy,safety,andtolerabilityofrimegepantorallydisintegrat
26(2):98–106
ingtabletfortheacutetreatmentofmigraine:arandomised,phase3,
14.vanCasterenDS,KurthT,DanserAHJ,TerwindtGM,MaassenVanDenBrink
doubleblind,placebocontrolledtrial.Lancet.394(10200):737–745
A(2021)SexdifferencesinresponsetoTriptans:asystematicreviewand
36.DodickDW,TepperSJ,FriedmanDI,GelfandAA,KellermanDJ,Schmidt
Metaanalysis.Neurology.96(4):162–170
PC(2018)UseofMostbothersomesymptomasaCoprimaryendpoint
15.YatesRA,TatenoM,NairnK,IkegamiA,DaneA,KempJ(2002)Thephar
inmigraineclinicaltrials:aposthocanalysisofthepivotalZOTRIPrand
macokineticsoftheantimigrainecompoundzolmitriptaninJapanese
omized,ControlledTrial.Headache58(7):986–992
andCaucasiansubjects.EurJClinPharmacol58(4):247–252
37.GoadsbyPJ,WietechaLA,DennehyEB,KucaB,CaseMG,AuroraSKetal
16.GeraudG,KeywoodC,SenardJM(2003)Migraineheadacherecurrence:
(2019)Phase3randomized,placebocontrolled,doubleblindstudyof
relationshiptoclinical,pharmacological,andpharmacokineticproperties
lasmiditanforacutetreatmentofmigraine.Brain.142(7):1894–1904
oftriptans.Headache.43(4):376–388
38.LiptonRB,DodickDW,AilaniJ,LuK,FinneganM,SzegediAetal(2019)
17.GoadsbyPJ,EdvinssonL(1993)Thetrigeminovascularsystemand
EffectofUbrogepantvsplaceboonpainandtheMostbothersome
migraine:studiescharacterizingcerebrovascularandneuropeptide
associatedsymptomintheacutetreatmentofmigraine:theACHIEVEII
changesseeninhumansandcats.AnnNeurol33(1):48–56
randomizedclinicaltrial.JAMA.322(19):1887–1898
18.CadyRK,VauseCV,HoTW,BigalME,DurhamPL(2009)Elevatedsaliva
calcitoningenerelatedpeptidelevelsduringacutemigrainepredict
therapeuticresponsetorizatriptan.Headache.49(9):1258–1266
Publisher’sNote
19.FerrariA,TiraferriI,NeriL,SternieriE(2011)Whypharmacokineticdiffer
SpringerNatureremainsneutralwithregardtojurisdictionalclaimsinpub
encesamongoraltriptanshavelittleclinicalimportance:acomment.J
lishedmapsandinstitutionalaffiliations.
HeadachePain12(1):5–12
20.PageMJ,McKenzieJE,BossuytPM,BoutronI,HoffmannTC,MulrowCD
etal(2021)ThePRISMA2020statement:anupdatedguidelineforreport
ingsystematicreviews.JClinEpidemiol134:178–189
21.DalkeyNC,HelmerHirschbergO(1962)Anexperimentalapplicationof
theDelphimethodtotheuseofexperts.RandCorp,SantaMonica |
|
